Starting Infliximab in Crohn's Disease: Alone or Paired With a Thiopurine
A single newly biologic-starting Crohn's disease patient, testing whether adding a thiopurine to infliximab is worth its own risks against the immunogenicity benefit the combination is meant to provide.
Grace M., a 52-year-old woman who accompanies her church choir, was diagnosed with moderate-to-severe ileal Crohn's disease eight months ago after a workup for persistent abdominal pain and unintentional weight loss she'd initially chalked up to a stressful year caring for her aging mother. Budesonide and mesalamine have not controlled her disease adequately — ongoing pain, a calprotectin still elevated at 310, and continued weight loss despite adequate caloric intake — and infliximab is the agreed next step. She has no history of malignancy, is EBV-seropositive from a childhood infection her records confirm, and takes no other regular medications beyond an occasional over-the-counter antihistamine for seasonal allergies.
The decision in front of the group now isn't whether to start infliximab — that part is settled — it's whether to start it alone or paired with a thiopurine from the outset. SONIC, the trial that actually tested this question directly, randomized biologic- and immunomodulator-naive Crohn's patients to infliximab alone, azathioprine alone, or the combination, and found significantly higher rates of corticosteroid-free clinical remission at week 26 with combination therapy than with either drug given alone — a benefit the trial's own pharmacokinetic data linked at least partly to higher infliximab trough levels and lower anti-drug antibody formation in the combination arm. That's a real, well-powered finding, not a marginal one. It's also not the whole picture: thiopurines carry their own dose-independent risks, most notably an elevated lymphoma risk that is highest in young men under 35 and in patients EBV-naive at the time of exposure — a risk profile that describes almost the opposite of who Grace is. She asked directly, once the two options were explained, whether the combination decision was really about her individually or just the default the trial recommends for everyone starting infliximab — a fair question, since SONIC's own headline result is an average across an enrolled population that included plenty of patients who don't share her particular age, sex, and EBV history.
Clinic, choosing monotherapy or combination at induction
I'd start combination therapy — infliximab with azathioprine from the outset. SONIC directly tested this exact question and found significantly higher rates of corticosteroid-free remission with combination therapy than with either drug alone, a benefit at least partly explained by higher infliximab trough levels and less anti-drug antibody formation. Given how she's responding so far to conventional therapy — not well — I'd want the strongest evidence-supported first attempt, not a monotherapy start with escalation held in reserve.
I'd want the lymphoma risk named plainly before this gets decided. Thiopurine-associated lymphoma risk is real, dose-independent, and elevated specifically in young men and in patients EBV-naive at exposure — not everyone SONIC's aggregate result applies to equally. Adding a second immunosuppressive drug isn't a free benefit; it's a real tradeoff that deserves being weighed against who's actually sitting in front of us, not just against the trial's average result.
That's exactly the right question to ask, and applying it to Grace specifically actually resolves this cleanly rather than leaving it a standoff. The highest-risk group for thiopurine-associated lymphoma is young men under 35 who are EBV-naive at the time of exposure — Grace is a 52-year-old woman, confirmed EBV-seropositive from childhood, sitting about as far from that risk profile as a patient can. SONIC's combination-therapy benefit is real and well-established; the safety concern that usually tempers it is specifically concentrated in a population she doesn't belong to. I'd start combination therapy with confidence here, precisely because her individual risk profile is the case where the trial's average benefit and the safety literature's usual caveat point the same direction rather than against each other.
Agreed: infliximab and azathioprine started together at induction, with routine complete blood counts monitored per standard thiopurine safety practice and an explicit note in the chart that the combination decision was risk-profile-specific — not a default to be applied unreflectively to a young male patient without EBV-serostatus confirmation, should that question come up again for a different patient.